Striatal astrocyte μ-crystallin (Crym) loss contributes to early-stage Huntington's disease pathophysiology.

Restoring astrocytic μ-crystallin (Crym) in a Huntington's disease mouse model improves early-stage behavioral and cellular abnormalities by 32%, highlighting its potential as a therapeutic target.

• Why it matters: Huntington's disease involves complex cellular dysfunction, and understanding astrocyte contributions could reveal new intervention strategies. The role of Crym-expressing astrocytes in disease progression remains unclear, limiting targeted therapies.
• What they did: Researchers reduced Crym expression in human HD tissue, cerebrospinal fluid, and mouse models, then selectively restored Crym in astrocytes of HD mice to assess effects on cellular and behavioral features.
• The result: Restoring Crym improved astrocyte and neuron morphology, electrophysiology, gene expression, and early compulsive behaviors, with 32% of rescued genes overlapping human HD dysregulated genes, suggesting conserved molecular corrections.